Published in BMC Cancer on April 30, 2010
What sort of follow-up services would Australian breast cancer survivors prefer if we could no longer offer long-term specialist-based care? A discrete choice experiment. Br J Cancer (2014) 0.92
Using technology to deliver cancer follow-up: a systematic review. BMC Cancer (2014) 0.91
Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer (2013) 0.86
Development and evaluation of evidence-informed clinical nursing protocols for remote assessment, triage and support of cancer treatment-induced symptoms. Nurs Res Pract (2013) 0.85
A retrospective study on telephone follow-up of anterior colporrhaphy by a specialized nurse. Int Urogynecol J (2014) 0.85
Options for early breast cancer follow-up in primary and secondary care - a systematic review. BMC Cancer (2012) 0.84
Telephone follow-up by a midlevel provider after laparoscopic inguinal hernia repair instead of face-to-face clinic visit. JSLS (2015) 0.81
Randomized controlled trial to test a computerized psychosocial cancer assessment and referral program: methods and research design. Contemp Clin Trials (2013) 0.80
Patient satisfaction with breast cancer follow-up care provided by family physicians. J Am Board Fam Med (2011) 0.77
A feasibility study of the Mini-AFTER telephone intervention for the management of fear of recurrence in breast cancer survivors: a mixed-methods study protocol. Pilot Feasibility Stud (2017) 0.75
A virtual outpatient department provides a satisfactory patient experience following endoscopy. Int J Colorectal Dis (2013) 0.75
Long-term prognostic outcome of cT1 gastric cancer patients who underwent laparoscopic gastrectomy after 5-year follow-up. Langenbecks Arch Surg (2016) 0.75
Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ (2009) 19.23
Multiple imputation: a primer. Stat Methods Med Res (1999) 17.79
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
Trials to assess equivalence: the importance of rigorous methods. BMJ (1996) 9.29
Patient satisfaction: a review of issues and concepts. Soc Sci Med (1997) 8.69
Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther (1974) 7.08
The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature. Health Technol Assess (2002) 6.37
Defining and measuring patient satisfaction with medical care. Eval Program Plann (1983) 6.15
Patient satisfaction: a valid concept? Soc Sci Med (1994) 5.53
Predictors of patient satisfaction. Soc Sci Med (2001) 4.29
How valid and reliable are patient satisfaction data? An analysis of 195 studies. Int J Qual Health Care (1999) 3.51
Effects of acquiescent response set on patient satisfaction ratings. Med Care (1978) 2.59
Follow up in breast cancer. BMJ (1995) 2.50
Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat (1996) 2.35
Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial. BMJ (2009) 1.95
Who should follow up cancer patients? Nurse specialist based outpatient care and the introduction of a phone clinic system. Clin Oncol (R Coll Radiol) (1994) 1.95
Social psychological determinants of patient satisfaction: a test of five hypothesis. Soc Sci Med (1982) 1.88
Follow-up for people with cancer: nurse-led services and telephone interventions. J Adv Nurs (2003) 1.56
Transitioning to cancer survivorship: plans of care. Oncology (Williston Park) (2009) 1.54
Is there a need to follow-up cancer patients? Eur J Cancer (1995) 1.51
The veil of experience: do consumers prefer what they know best? Health Econ (2000) 1.43
Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer (2007) 1.36
Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. J Adv Nurs (2009) 1.36
Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer (2004) 1.30
Patient initiated follow up of breast cancer. Psychooncology (2002) 1.21
[The risk of cancer in the Netherlands]. Ned Tijdschr Geneeskd (2008) 1.16
Can telephone counseling post-treatment improve psychosocial outcomes among early stage breast cancer survivors? Psychooncology (2010) 1.15
Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study. Eur J Oncol Nurs (2004) 1.12
A preliminary study of patients' perceptions of routine follow-up after treatment for breast cancer. Eur J Oncol Nurs (2000) 1.00
Periodic follow-up after breast cancer and the effect on survival. Eur J Surg (2001) 0.95
Structure and reliability of Ware's Patient Satisfaction Questionnaire III: patients' satisfaction with oncological care in the Netherlands. Med Care (2003) 0.91
Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.90
Patients' expectations for follow-up in breast cancer--a preliminary, questionnaire-based study. Breast (2008) 0.88
Customer satisfaction in the emergency department. Emerg Med Clin North Am (2004) 0.88
The meaning of the breast cancer follow-up experience for the women who attend. Eur J Oncol Nurs (2002) 0.87
Improving the quality and efficiency of follow-up after curative treatment for breast cancer--rationale and study design of the MaCare trial. BMC Cancer (2007) 0.83
Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis. Clin Oncol (R Coll Radiol) (1999) 0.79
[Guideline 'Treatment of breast cancer 2008' (revision)]. Ned Tijdschr Geneeskd (2008) 0.77
Patient centred care: essential but probably not sufficient. Qual Saf Health Care (2002) 0.77
Automated telephone follow-up after breast cancer: an acceptability and feasibility pilot study. Br J Cancer (2008) 0.77
Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol (2008) 4.60
Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet (2004) 3.50
Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 3.24
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest (2009) 3.01
Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol (2006) 2.84
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Tailoring the atomic structure of graphene nanoribbons by scanning tunnelling microscope lithography. Nat Nanotechnol (2008) 2.49
Integrated multidisciplinary diagnostic approach for dementia care: randomised controlled trial. Br J Psychiatry (2008) 2.45
Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41
Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys (2003) 2.41
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys (2007) 2.21
Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol (2009) 2.21
Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol (2013) 2.11
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med (2008) 2.08
In unselected patients, elective single embryo transfer prevents all multiples, but results in significantly lower pregnancy rates compared with double embryo transfer: a randomized controlled trial. Hum Reprod (2005) 1.90
The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer (2007) 1.76
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol (2012) 1.68
Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.67
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys (2009) 1.67
Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens (2007) 1.66
Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys (2010) 1.66
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol (2009) 1.59
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
A literature review of electronic portal imaging for radiotherapy dosimetry. Radiother Oncol (2008) 1.53
Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol (2006) 1.51
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol (2008) 1.51
Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations. PLoS Genet (2006) 1.50
Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.49
Economic evaluation of deep anterior lamellar keratoplasty versus penetrating keratoplasty in The Netherlands. Am J Ophthalmol (2011) 1.44
Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol (2010) 1.44
Renal artery stenosis: cost-effectiveness of diagnosis and treatment. Radiology (2007) 1.43
Economic evaluation of endothelial keratoplasty techniques and penetrating keratoplasty in the Netherlands. Am J Ophthalmol (2012) 1.40
Automated Delineation of Lung Tumors from CT Images Using a Single Click Ensemble Segmentation Approach. Pattern Recognit (2013) 1.36
The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev (2006) 1.35
Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2006) 1.34
Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline. World J Gastroenterol (2007) 1.34
Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.32
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol (2012) 1.31
Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer. Radiother Oncol (2003) 1.28
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med (2011) 1.25
Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2005) 1.24
Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys (2003) 1.24
Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys (2010) 1.23
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.22
Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol (2002) 1.22
The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol (2005) 1.22
A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys (2006) 1.22
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med (2012) 1.21
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys (2005) 1.18
Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol (2004) 1.17
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys (2009) 1.15
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer (2011) 1.15
How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol (2010) 1.15
Performance of the EQ-5D and the EQ-5D+C in elderly patients with cognitive impairments. Health Qual Life Outcomes (2007) 1.14
Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer (2005) 1.14
First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol (2003) 1.14
Identification of differentially expressed genes in mouse kidney after irradiation using microarray analysis. Radiat Res (2004) 1.14
Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys (2004) 1.13
Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patients. Radiother Oncol (2007) 1.13
Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev (2007) 1.12
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence (2013) 1.11
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther (2014) 1.11
Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol (2007) 1.11
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.11
The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol (2009) 1.09
Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys (2007) 1.08
The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev (2010) 1.08
Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiother Oncol (2009) 1.08
Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy. Br J Psychiatry (2008) 1.08
Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys (2008) 1.08
Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.07
Targeting hypoxia tolerance in cancer. Drug Resist Updat (2004) 1.07
Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. Int J Radiat Oncol Biol Phys (2008) 1.07
Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol (2006) 1.06
Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol (2008) 1.06
Evaluation of nonrigid registration models for interfraction dose accumulation in radiotherapy. Med Phys (2009) 1.05
Health-related quality of life in patients surviving non-small cell lung cancer. Thorax (2010) 1.05
A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One (2011) 1.05
Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol (2012) 1.05
Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol (2007) 1.05
PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging (2010) 1.04
Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem (2009) 1.04
Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated Salmonella. Cancer Biol Ther (2006) 1.03
Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J Biol Chem (2009) 1.03
Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol (2002) 1.03
Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol (2003) 1.02
Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol (2010) 1.02
Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer: re-evaluation of dose in normal lung tissue. Radiother Oncol (2003) 1.02
When to wait for more evidence? Real options analysis in proton therapy. Oncologist (2011) 1.02
Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol (2009) 1.02
Literature review on monitoring technologies and their outcomes in independently living elderly people. Disabil Rehabil Assist Technol (2014) 1.02
Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol (2005) 1.01
Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. Radiother Oncol (2013) 1.01
Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol (2010) 1.01
Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol (2007) 1.00
Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.00
Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys (2008) 0.99